Reach Us +441518081309


Case Report: LDAC for the Treatment of Post-Splenectomy Newly Diagnosed PMF Patent with Oral Treatment Inability

Primary myelofibrosis (PMF) is a hematologic malignancy belonging to Ph negative myeloproliferative neoplasms (MPN), and it is commonly characterized by a higher risk of acute myeloid leukemia (AML) transformation. The aim of this case report is a demonstration of treatment with low dose cytarabine (LDAC) for a non-transformed newly diagnosed PMF patient with the inability of oral therapy and post-splenectomy complications.


Harutyunyan L, Meliksetyan K, Oganesyan A, Oseyan H, Khachatryan H and Hakobyan Y

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Abstracted/Indexed in
  • Google Scholar
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs
  • Euro Pub

View More »

Flyer image
Linklerimi silersen Site sahibine iletirim aš???.